

# Clinical Trial Protocol

## Iranian Registry of Clinical Trials

10 Jun 2026

### Comparison of the effects of Arginine and Citrulline supplementation on the prognosis of critically ill patients in intensive care unit receiving enteral nutrition

#### Protocol summary

##### Summary

Our aim is to compare the effects of Arginine and Citrulline supplementation on the prognosis of critically ill patients in intensive care unit receiving enteral nutrition. A total of 105 critically traumatic patients admitted to the intensive care units and receive enteral nutritional support will be recruited and randomly allocated into three groups. Patients are head trauma patients grade 2,3. Two groups will be intervened each by citrulline or arginine (10 g/day for 10 days) and the third group will receive just enteral nutritional support without immune supplements. Patients are between 20-70 years old, with BMI:18.5-30, and eligible for enteral nutrition support. Septic, Hemodynamically and metabolically unstable patients, and more than 3 days NPO will be excluded from the study. This clinical trial will be executed in 5 trauma ICUs at a trauma center in teaching hospital of Kamyab in Mashhad. Three groups will be compared for clinical severity (evaluated with APACHE II score), length of hospital stay and complications, inflammatory state (CRP, IL6) nutritional markers (RBP, Pre-Albumin), lipid profile (LDL-C, HDL-C, Cholesterol, Triglycerid), plasma glucose, electrolytes, liver enzymes levels (AST, ALT, ALP, LDH total), NO production, PAB (Pro-oxidant and Anti-oxidant Balance), urea and creatinine. Serum levels of Arginine, Citrulline, Ornithine, Glutamine and lysine.

#### General information

##### Acronym

##### IRCT registration information

IRCT registration number: **IRCT201108027199N1**  
Registration date: **2011-10-28, 1390/08/06**  
Registration timing: **registered\_while\_recruiting**

Last update:

Update count: **0**

##### Registration date

2011-10-28, 1390/08/06

##### Registrant information

###### Name

Bahareh Barkhidarian

###### Name of organization / entity

Mashhad university of medical science

###### Country

Iran (Islamic Republic of)

###### Phone

+98 51 1844 5309

###### Email address

barkhib881@mums.ac.ir

##### Recruitment status

###### Recruitment complete

##### Funding source

Mashhad university of medical sciences and P.N.C food supplement company

##### Expected recruitment start date

2011-09-29, 1390/07/07

##### Expected recruitment end date

2011-12-28, 1390/10/07

##### Actual recruitment start date

empty

##### Actual recruitment end date

empty

##### Trial completion date

empty

##### Scientific title

Comparison of the effects of Arginine and Citrulline supplementation on the prognosis of critically ill patients in intensive care unit receiving enteral nutrition

##### Public title

Comparison of Arginine and Citrulline

### **Purpose**

Supportive

### **Inclusion/Exclusion criteria**

Inclusion criteria: AGE:20-70 years old ;BMI:18.5-30

Exclusion criteria: hemodynamically and metabolically unstable patients; more than 3 days NPO; any condition that we can not use enteral feeding

### **Age**

From **20 years** old to **70 years** old

### **Gender**

Both

### **Phase**

N/A

### **Groups that have been masked**

*No information*

### **Sample size**

Target sample size: **105**

### **Randomization (investigator's opinion)**

Randomized

### **Randomization description**

### **Blinding (investigator's opinion)**

Not blinded

### **Blinding description**

### **Placebo**

Not used

### **Assignment**

Parallel

### **Other design features**

## **Secondary Ids**

empty

## **Ethics committees**

### 1

#### **Ethics committee**

##### **Name of ethics committee**

Mashad university of medical sciences

##### **Street address**

Sakhteman ghoreishi, Daneshgah street

##### **City**

Mashad

##### **Postal code**

91375345

#### **Approval date**

2011-01-15, 1389/10/25

#### **Ethics committee reference number**

89479

## **Health conditions studied**

### 1

#### **Description of health condition studied**

head trauma patients

#### **ICD-10 code**

S06

#### **ICD-10 code description**

Intracranial injury

## **Primary outcomes**

### 1

#### **Description**

death

#### **Timepoint**

28 days follow up

#### **Method of measurement**

daily assessment

### 2

#### **Description**

body mass index

#### **Timepoint**

day 0 and day 11 (first and last days of intervention)

#### **Method of measurement**

based on BMI equation

### 3

#### **Description**

ventilator depending

#### **Timepoint**

during hospital stay

#### **Method of measurement**

daily assessment

### 4

#### **Description**

length of hospital stay

#### **Timepoint**

in day of release

#### **Method of measurement**

based on date of admission and release

### 5

#### **Description**

ALT

#### **Timepoint**

day 0 and day 11 (first and last days of intervention)

#### **Method of measurement**

based on laboratory measurement

### 6

#### **Description**

AST

#### **Timepoint**

day 0 and day 11 (first and last days of intervention)

#### **Method of measurement**

based on laboratory measurement

### 7

#### **Description**

SEVERITY OF ILLNESS

#### **Timepoint**

day 0 and day 11 (first and last days of intervention)  
**Method of measurement**  
APACHEII

## 8

**Description**  
LDH  
**Timepoint**  
day 0 and day 11 (first and last days of intervention)  
**Method of measurement**  
based on laboratory measurement

## 9

**Description**  
ALP  
**Timepoint**  
day 0 and day 11 (first and last days of intervention)  
**Method of measurement**  
based on laboratory measurement

## 10

**Description**  
FBS  
**Timepoint**  
day 0 and day 11 (first and last days of intervention)  
**Method of measurement**  
based on laboratory measurement

## 11

**Description**  
BUN  
**Timepoint**  
day 0 and day 11 (first and last days of intervention)  
**Method of measurement**  
based on laboratory measurement

## 12

**Description**  
CREATININE  
**Timepoint**  
day 0 and day 11 (first and last days of intervention)  
**Method of measurement**  
based on laboratory measurement

## 13

**Description**  
CHOLESTROL  
**Timepoint**  
day 0 and day 11 (first and last days of intervention)  
**Method of measurement**  
based on laboratory measurement

## 14

**Description**  
LDL  
**Timepoint**  
day 0 and day 11 (first and last days of intervention)

**Method of measurement**  
based on laboratory measurement

## 15

**Description**  
HDL  
**Timepoint**  
day 0 and day 11 (first and last days of intervention)  
**Method of measurement**  
based on laboratory measurement

## 16

**Description**  
TG  
**Timepoint**  
day 0 and day 11 (first and last days of intervention)  
**Method of measurement**  
based on laboratory measurement

## 17

**Description**  
BILLIRUBIN TOTAL  
**Timepoint**  
day 0 and day 11 (first and last days of intervention)  
**Method of measurement**  
based on laboratory measurement

## 18

**Description**  
DIRECT BILLIRUBINE  
**Timepoint**  
day 0 and day 11 (first and last days of intervention)  
**Method of measurement**  
based on laboratory measurement

## 19

**Description**  
Na  
**Timepoint**  
day 0 and day 11 (first and last days of intervention)  
**Method of measurement**  
based on laboratory measurement

## 20

**Description**  
potassium  
**Timepoint**  
day 0 and day 11 (first and last days of intervention)  
**Method of measurement**  
based on laboratory measurement

## 21

**Description**  
total calcium  
**Timepoint**  
day 0 and day 11 (first and last days of intervention)  
**Method of measurement**

based on laboratory measurement

## **22**

### **Description**

magnesium

### **Timepoint**

day 0 and day 11 (first and last days of intervention)

### **Method of measurement**

based on laboratory measurement

## **23**

### **Description**

phosphor

### **Timepoint**

day 0 and day 11 (first and last days of intervention)

### **Method of measurement**

based on laboratory measurement

## **24**

### **Description**

albumine

### **Timepoint**

day 0 and day 11 (first and last days of intervention)

### **Method of measurement**

based on laboratory measurement

## **25**

### **Description**

total protein

### **Timepoint**

day 0 and day 11 (first and last days of intervention)

### **Method of measurement**

based on laboratory measurement

## **26**

### **Description**

nitric oxide

### **Timepoint**

day 0 and day 11 (first and last days of intervention)

### **Method of measurement**

based on laboratory measurement

## **27**

### **Description**

pro oxidant \_ anti oxidant balance

### **Timepoint**

day 0 and day 11 (first and last days of intervention)

### **Method of measurement**

based on laboratory measurement

## **28**

### **Description**

pre albumine

### **Timepoint**

day 0 and day 11 (first and last days of intervention)

### **Method of measurement**

based on laboratory measurement

## **29**

### **Description**

CRP

### **Timepoint**

day 0 and day 11 (first and last days of intervention)

### **Method of measurement**

based on laboratory measurement

## **30**

### **Description**

IL6

### **Timepoint**

day 0 and day 11 (first and last days of intervention)

### **Method of measurement**

based on laboratory measurement

## **31**

### **Description**

SERUM AMINO ACIDS(ARGININE, GLUTAMINE, CITRULLINE, LYSINE, ORNITHINE)

### **Timepoint**

day 0 and day 11 (first and last days of intervention)

### **Method of measurement**

based on laboratory measurement

## **32**

### **Description**

weight

### **Timepoint**

day 0 and day 11 (first and last days of intervention)

### **Method of measurement**

based on laboratory measurement

## **33**

### **Description**

Mid Arm Circumferences

### **Timepoint**

day 0 and day 11 (first and last days of intervention)

### **Method of measurement**

based on laboratory measurement

## **Secondary outcomes**

### **1**

#### **Description**

side effect

#### **Timepoint**

during intervention

#### **Method of measurement**

daily assessment

## **Intervention groups**

### **1**

#### **Description**

Arginine group receives 10 g/day arginine powder in 2

separate 5 gram doses

**Category**

Treatment - Other

2

**Description**

Citrulline group receives 10 g/day citrulline powder in 2 separated 5 gram doses

**Category**

Other

3

**Description**

control group will not receive any supplement

**Category**

Other

**Recruitment centers**

1

**Recruitment center**

**Name of recruitment center**

shahid kamyab hospital

**Full name of responsible person**

**Street address**

**City**

mashad

**Sponsors / Funding sources**

1

**Sponsor**

**Name of organization / entity**

Mashad university of medical sciences

**Full name of responsible person**

Mashad university of medical sciences

**Street address**

Sakhteman Ghoreishi, Daneshgah street, Mashad

**City**

Mashad

**Grant name**

**Grant code / Reference number**

**Is the source of funding the same sponsor organization/entity?**

Yes

**Title of funding source**

Mashad university of medical sciences

**Proportion provided by this source**

**Public or private sector**

empty

**Domestic or foreign origin**

empty

**Category of foreign source of funding**

empty

**Country of origin**

**Type of organization providing the funding**

empty

2

**Sponsor**

**Name of organization / entity**

Karen nutriline co

**Full name of responsible person**

Ali Mazidi

**Street address**

number2, Atefi street, Afrigha blvd

**City**

Tehran

**Grant name**

**Grant code / Reference number**

**Is the source of funding the same sponsor organization/entity?**

Yes

**Title of funding source**

Karen nutriline co

**Proportion provided by this source**

**Public or private sector**

empty

**Domestic or foreign origin**

empty

**Category of foreign source of funding**

empty

**Country of origin**

**Type of organization providing the funding**

empty

**Person responsible for general inquiries**

**Contact**

**Name of organization / entity**

Mashad university of medical sciences

**Full name of responsible person**

Bahareh Barkhidarian

**Position**

MSC

**Other areas of specialty/work**

**Street address**

Paradise Daneshgah

**City**

Mashad

**Postal code**

91779-48564

**Phone**

+98 51 1844 5309

**Fax**

**Email**

BARKHIB881@MUMS.AC.IR

**Web page address**

**Person responsible for scientific inquiries**

**Contact**

**Name of organization / entity**

Mashad university of medical sciences

**Full name of responsible person**

Mohammad Safarian

**Position**

MD, MSc, PhD

**Other areas of specialty/work****Street address**

Paradise Daneshgah

**City**

Mashad

**Postal code**

91779-48564

**Phone**

+98 51 1800 2359

**Fax**

+98 51 1882 8574

**Email**

safarianm@mums.ac.ir ms11@alumni.soton.ac.uk

**Web page address**

WWW.MUMS.AC.IR

**Person responsible for updating data****Contact****Name of organization / entity**

Mashad university of medical sciences

**Full name of responsible person**

Bahareh Barkhidarian

**Position****Other areas of specialty/work****Street address****City****Postal code****Phone**

+98 51 1800 2359

**Fax****Email**

BARKHIB881@MUMS.AC.IR

**Web page address****Sharing plan****Deidentified Individual Participant Data Set (IPD)***empty***Study Protocol***empty***Statistical Analysis Plan***empty***Informed Consent Form***empty***Clinical Study Report***empty***Analytic Code***empty***Data Dictionary***empty*